Generic Name and Formulations:
Metoprolol succinate ext-rel, hydrochlorothiazide; 25/12.5mg, 50/12.5mg, 100/12.5mg; tabs.
Concordia Pharmaceuticals Inc.
Indications for DUTOPROL:
Individualize. Initially 25/12.5mg once daily; may titrate at 2-week intervals to max 200mg/25mg once daily. May substitute for individual titrated components. Severe renal impairment (CrCl ≤30mL/min): not established.
Cardiogenic shock. Decompensated heart failure. Sinus bradycardia. Sick sinus syndrome. 2nd- or 3rd-degree AV block unless paced. Anuria. Sulfonamide allergy.
Cardiac ischemia after abrupt discontinuation.
Ischemic heart disease. Worsening cardiac failure (reduce or interrupt dose if necessary). Bronchospastic disease. Monitor HR and rhythm; reduce dose or discontinue if severe bradycardia occurs. Pheochromocytoma. Major surgery. Renal or hepatic impairment. Volume depletion. Diabetes and hypoglycemia. Thyrotoxicosis (hyperthyroidism). Peripheral vascular disease. Acute myopia. Secondary angle-closure glaucoma. SLE. Gout. Post-sympathectomy. Avoid abrupt cessation (reduce dose over 1–2 weeks and monitor). Monitor electrolytes. Pregnancy (Cat.C). Nursing mothers.
Cardioselective beta-blocker + diuretic.
Additive effects with catecholamine-depleting drugs (eg, reserpine, MAOIs). Potentiated by CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine, propafenone). Risk of bradycardia with digitalis, clonidine, diltiazem, verapamil. Potentiated by alcohol, barbituates, narcotics, other antihypertensives. Hypokalemia with corticosteroids, ACTH. May increase lithium toxicity. Antagonized by NSAIDs (monitor). Adjust antidiabetic drugs. Decreased absorption with cholestyramine and colestipol resins. Antagonizes epinephrine. Possible increased response to muscle relaxants (eg, tubocurarine). Beta-blockers may mask signs of hypoglycemia. May interfere with parathyroid tests.
Nasopharyngitis, fatigue, dizziness, back pain, nausea; bronchospasm, bradycardia, CHF, heart block, vision disorders.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML